← Back to Search

Cytokine

Pegilodecakin + Pembrolizumab for Non-Small Cell Lung Cancer (Cypress 1 Trial)

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of response to death due to any cause (up to 24 months)
Awards & highlights

Summary

To compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of response to death due to any cause (up to 24 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of response to death due to any cause (up to 24 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of Participants Who Achieved an Objective Response Rate (ORR)
Secondary study objectives
Duration of Response (DOR)
Overall Survival (OS)
Percentage of Participants Who Achieved a Disease Control Rate (DCR)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Pegilodecakin + PembrolizumabExperimental Treatment2 Interventions
Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (\>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm. Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle.
Group II: PembrolizumabActive Control1 Intervention
Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Pegilodecakin
Not yet FDA approved

Find a Location

Who is running the clinical trial?

ARMO BioSciencesIndustry Sponsor
7 Previous Clinical Trials
1,017 Total Patients Enrolled
Eli Lilly and CompanyLead Sponsor
2,640 Previous Clinical Trials
3,221,543 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,358 Previous Clinical Trials
417,989 Total Patients Enrolled
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top